Search Tag: prostate cancer

IMAGING Management

MRI + Prostate-Specific Antigen Screening Improves Cancer Detection

2015 25 Mar

Early results from the Göteborg randomised screening trial show that the use of MRI alongside conventional prostate cancer screening may offer improved cancer detection and may help in avoiding unnecessary biopsies. The Göteborg Trial is the Swedish arm of the European Randomised Study of Screening for Prostate Cancer, the largest randomised prostate... Read more

IMAGING Management

Regional Behaviours May Contribute To Inappropriate Imaging

2015 12 Mar

A study published online in JAMA Oncology has found an association between high rates of inappropriate imaging for breast cancer and prostate cancer, diseases for which specialist physicians do not overlap. The revelation suggests that regional infrastructure and culture may contribute to the sometimes inappropriate utilisation of healthcare resources,... Read more

IMAGING Management

RSI-MRI Detects Spread of Cancer Beyond Prostate

2015 11 Mar

A pilot clinical study involving nine prostate cancer patients has compared standard MRI with a new clinical imaging technique that has the ability to identify less severe forms of the disease, potentially saving patients unnecessary treatment. The new technique generates more precise images so that surgeons are better able to determine the extent... Read more

IMAGING Management

Prostate Cancer Diagnosis: Targeted MRI/Ultrasound Beats Standard Biopsy

2015 30 Jan

A large-scale study shows that targeted biopsy using new fusion technology that combines magnetic resonance imaging (MRI) with ultrasound is more effective than standard biopsy in detecting high-risk prostate cancer. Researchers found that 30 percent more high-risk prostate cancers were diagnosed with targeted fusion-guided biopsy than with standard... Read more

IMAGING Management

New MRI Technique Improves Prostate Cancer Detection

2015 08 Jan

A new imaging technique that measurably improves upon current prostate imaging could have significant implications for how patients with prostate cancer are ultimately treated. The new method called restriction spectrum imaging-MRI (RSI-MRI) was developed by researchers from the University of California, San Diego School of Medicine, and University... Read more

Executive Health Management

Aggressive Prostate Cancer Treatment Defies Guidelines

2014 10 Dec

The first study of its kind by UCLA researchers has found that despite the fact that more than half of prostate cancer patients 66 years of age and older have life expectancies of less than ten years, half of them are over-treated for prostate cancer with surgery, radiation or brachytherapy. National guidelines recommend that men with life expectancy of... Read more

IT Management

How 3D Printing is Reshaping Medical Practice

2014 08 Dec

Three-dimensional (3D) printing is increasingly being used in medical practice, but its implications for healthcare may be complex, according to a commentary published in JAMA . Although questions remain about how best to use the technology, experts say that 3D printing is already changing patient care. In fact, 3D printing has been used in dentistry... Read more

Pharmacy Management

Prescriptions for Bisphosphonates Remain Low

2014 08 Dec

According to a study published in JAMA, prescriptions for bisphosphonates, a class of drugs used to strengthen bone for men on androgen deprivation therapy (ADT) and for those at high risk of subsequent fractures, remain low despite guidelines recommending their use.   ADT is widely used in men suffering from prostate cancer. Common adverse effects... Read more

Lab Management

Biomarker Predicts Aggressive Prostate Cancer

2014 04 Oct

A new study has identified a biomarker living beside the KLK3 gene that can predict which GS7 prostate cancer patients will have a more aggressive form of cancer, according to a Science Newsline report. The KLK3 gene is located on chromosome 19 and is responsible for encoding the prostate-specific antigen (PSA). Results of the study published in... Read more

IMAGING Management

FDA Panel Disapproves Of HIFU For Prostate Cancer

2014 05 Aug

The company marketing Ablatherm Integrated Imaging High Intensity Focused Ultrasound (HIFU), used to treat low-risk prostate cancer, has failed to get the nod of U.S. Food and Drug Administration (FDA) on its premarket approval application. HIFU, which has been used in other countries for about 15 years, is marketed in Europe by EDAP TMS, a French... Read more